Can lactating women take ivonib/Tosuvo safely?

Whether Ivosidenib can be safely taken by breastfeeding women is an important medical question. Ivonib is a targeted drug mainly used to treat IDH1 mutant acute myeloid leukemia (AML). Although ivonib has shown significant efficacy in the treatment of AML, its use in breastfeeding women still needs to be carefully considered.

The safety data of ivonib in clinical studies mainly focus on adult patients, and there are relatively few studies on lactating women. Whether the drug can be excreted through breast milk and its possible effects on the baby are issues that require special attention. Although there is currently no substantial clinical evidence that ivosidenib is significantly transmitted through breast milk, it is possible that ivosidenib may be excreted in breast milk depending on the nature of the drug and its metabolism in the body. Because many drugs are present in high concentrations in breast milk and because the infant's immune system and liver metabolism are immature, infants taking these drugs may experience adverse reactions.

Therefore, according to the guidelines for the use of ivosidenib and the recommendations of medical experts, lactating women should avoid breastfeeding during treatment with ivosidenib. That's because, while avosidenib has levels in the blood that make it effective in treating leukemia, there's still some uncertainty about whether the drug is safely excreted into breast milk. To ensure the safety of the infant, it is generally recommended to avoid breastfeeding during treatment with ivonib and for one month after the last dose.

For women who need to be treated with ivosidenib while breastfeeding, their doctor may recommend temporarily discontinuing breastfeeding and providing an alternative feeding regimen, such as formula. In addition, doctors may monitor patients more closely during treatment to ensure the safety of mother and baby.

Reference materials: https://www.tibsovo.com/